Premium
Laboratory monitoring of new anticoagulants
Author(s) -
Castellone Donna D.,
Van Cott Elizabeth M.
Publication year - 2010
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.21607
Subject(s) - argatroban , bivalirudin , fondaparinux , medicine , intensive care medicine , discovery and development of direct thrombin inhibitors , anticoagulant , hirudin , direct thrombin inhibitor , dabigatran , warfarin , atrial fibrillation , thrombosis , venous thromboembolism , thrombin , myocardial infarction , platelet , percutaneous coronary intervention
Maintaining a balance between bleeding and clotting has always been a challenge in treating coagulation disorders. A perturbation in that balance can be associated with substantial morbidity and mortality. As a result, anticoagulant monitoring is extremely important, and inappropriate testing may lead to complications. There are now a variety of new anticoagulant drugs in clinical use including several direct thrombin inhibitors (DTIs), such as argatroban, bivalirudin, and hirudin, as well as a Factor Xa inhibitor, fondaparinux. There are pitfalls associated with some of the currently used laboratory monitoring tests, and newer alternative laboratory monitoring tests have been investigated (Walenga and Hoppensteadt, Semin Thromb Hemost 2004;30:683–695). In addition, laboratory testing can assist with transitioning patients from DTI to warfarin therapy. Am. J. Hematol. 2010. © 2009 Wiley‐Liss, Inc.